HOME > COMMENTARY
COMMENTARY
-
Viable Third-Party Review System Required for Drug Makers’ Advertisements
July 7, 2015
-
Japan Compassionate Use System a “Stick” for Drug Makers? Incentives to Counter Their Burden Needed
June 22, 2015
-
Generic Makers Baffled by New Govt Target, Quality and Supply Concerns Linger
June 15, 2015
-
Thorny Path Ahead toward Trial Rollout of Cost-Effective Assessment in FY2016; Chuikyo to Begin Discussions on May 27
May 26, 2015
-
1 Year after Viagra Generic Debut, Freely Priced Generics Seem to Be Bringing Benefits
May 8, 2015
-
Opdivo Offers Hope but Poses Challenges Too, Cautious Approach Needed to Expand Indications
April 27, 2015
-
Will Japanese Drug Makers Become More Discerning in Unearthing Seeds?
April 17, 2015
-
Patient Subsidy System Expanded for Intractable Diseases, What about Incentives for Drug Makers?
April 7, 2015
-
Abe Pledges Biosimilar Promotion, but Doctor Misconception and Lack of Incentives Remain as Challenges
March 30, 2015
-
SGLT-2 Inhibitor Sales Would Plunge If Used Only in Younger, Obese Patients, but Cautious Administration Warranted
March 17, 2015
-
Uncertainty Swirling around Possible Drug Price Cuts for 3 Straight Years
March 16, 2015
-
Drug Repositioning May Promise Greater Chance of Success, but Problems Remain
March 6, 2015
-
As Adjuvant Development Race Heats Up, New Databases Could Turn Japan into Global Vaccine Powerhouse
February 16, 2015
-
Japan Poised to Tap Its Version of “Compassionate Use” to Combat Challenges Left for Unapproved Drugs
February 2, 2015
-
Open Innovation Bandwagon Gathers Pace for Efficient Drug Discovery
January 26, 2015
-
Have AGs Finally Become a Good Option to Counter Generics?
January 19, 2015
-
Will Legal Regulation Propel or Stymie Clinical Research? “Risk-Based” Approach Holds Key
January 13, 2015
-
Can Pharmas and Wholesalers Work to Dispel “Negative Primary Margins on Sales”?
December 22, 2014
-
April-Sept. Earnings Signal Watershed in Japan’s Shift to Generics
December 15, 2014
-
Wonder Drug? Savior? Avigan Clinical Trial for Ebola May Not Provide Clear-Cut Answer
December 5, 2014
ページ
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
